Αρχειοθήκη ιστολογίου

Σάββατο 22 Δεκεμβρίου 2018

Five-year outcomes of sparing level IB in node-positive, human papillomavirus–associated oropharyngeal carcinoma: A safety and efficacy analysis

Publication date: February 2019

Source: Oral Oncology, Volume 89

Author(s): R.B. Ross, A. Juloori, V. Varra, M.C. Ward, S. Campbell, N.M. Woody, E. Murray, P. Xia, J.F. Greskovich, S.A. Koyfman, N.P. Joshi

Abstract
Introduction

The conformality of modern intensity modulated radiation therapy (IMRT) allows avoidance of the submandibular glands (SMG) in select patients, potentially improving late xerostomia. This study explores the safety and efficacy of this approach in select oropharyngeal carcinoma (OPC) patients.

Methods

Patients with T1-2N+ human papillomavirus (HPV)-associated OPC treated with definitive IMRT at one institution from 2009 to 2014 were identified. Patients were divided into 3 groups: bilateral level IB targeted (A, n = 16), a single level IB targeted (B, n = 61), and bilateral IB spared (C, n = 9). Outcomes were reviewed to identify the rate of level IB regional recurrence. Odds ratios were calculated for xerostomia between groups.

Results

Level Ib was targeted in 93 instances (54.1%) and avoided in 79 instances (45.9%). Mean SMG doses were significantly lower when level IB was spared compared to when targeted (37.5 Gy vs 67.5 Gy; P < 0.0001). Median doses to oral cavity decreased with increasing level Ib sparing (40.7 Gy [A] vs 35.4 Gy [B] vs 30.7 [C]; P = 0.002). The rate of late grade ≥2 xerostomia was significantly lower in patients with bilateral 1b sparing (53% in A vs 0% in C; P = 0.007). Sparing 1b unilaterally resulted in a non-significant decrease in late grade ≥2 xerostomia (P = 0.181). No regional failures were identified in levels IB (median follow up = 59.3 months).

Conclusion

Sparing level IB is safe in T1-2N+ HPV+ OPC. Avoiding level Ib translates into significantly lower SMG and oral cavity doses. Larger studies are needed to validate these findings and the impact of this technique.



http://bit.ly/2V4bgx5

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου